Llwytho...

Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab

BACKGROUND: Immune checkpoint inhibitors (ICIs) are currently the standard therapy in advanced non-small cell lung cancer (NSCLC); however, there is no well-established prognostic biomarker. We investigated the relationship between survival outcomes and three peripheral blood biomarkers, including t...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Transl Lung Cancer Res
Prif Awduron: Sánchez-Gastaldo, Amparo, Muñoz-Fuentes, Miguel A., Molina-Pinelo, Sonia, Alonso-García, Miriam, Boyero, Laura, Bernabé-Caro, Reyes
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: AME Publishing Company 2021
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8264316/
https://ncbi.nlm.nih.gov/pubmed/34295658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-21-156
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!